News
MGNX
15.70
-3.27%
-0.53
Weekly Report: what happened at MGNX last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at MGNX last week (0408-0412)?
Weekly Report · 04/15 09:04
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
TipRanks · 04/12 10:30
Buy Rating Affirmed for MacroGenics with Promising Vobra Duo Data and Anticipated 2024 Clarifications
TipRanks · 04/10 06:18
Macrogenics Raised to Buy From Hold by TD Cowen
Dow Jones · 04/09 10:47
TD Cowen Upgrades Macrogenics to Buy
Benzinga · 04/09 10:37
MACROGENICS INC <MGNX.O>: TD COWEN RAISES TO BUY FROM HOLD
Reuters · 04/09 10:35
Validea Detailed Fundamental Analysis - MGNX
NASDAQ · 04/08 20:06
Weekly Report: what happened at MGNX last week (0401-0405)?
Weekly Report · 04/08 09:05
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
MacroGenics, Inc. Is advancing the use of vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. The global prostate cancer market size is estimated to reach $27.51 billion by 2032. The company announced a positive safety update from its phase 2 TAMARACK study. There are two major milestones ahead for MacroGenics in 2024.
Seeking Alpha · 04/05 06:31
Look Out For These 6 Stocks As Analysts Predicts Major Gains, One Up To 82%
Investment analysts have revised their price targets upwards for six major stocks this week. The revised targets include four U.S.-listed companies. The most significant upgrade is for a biopharmaceutical company MacroGenics. The company is expected to see an 82% surge over the next year.
Benzinga · 04/05 06:15
Stocks Slide in Today's Afternoon Trading Session
NASDAQ · 04/04 19:27
MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate
MacroGenics Inc provides update on the Phase 2 TAMARACK study of vobra duo for metastatic castration-resistant prostate cancer. The company plans to provide updated interim data on the study by May 31. JMP Securities analysts say they are impressed by the enhanced safety profile of the drug.
Benzinga · 04/04 18:15
BUZZ-U.S. STOCKS ON THE MOVE-US banks, Hertz, Spirit,
Wall Street's main stock indexes advanced on Thursday. The Dow Jones Industrial Average was up 0.39% at 39,279.3. The top three S&P 500 percentage gainers were Enphase Energy, Delta Air Lines. The Nasdaq Composite was up 1.06%.
Reuters · 04/04 18:02
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. The company issued strong preliminary first-quarter net sales guidance. TC Biopharm (Holdings) Plc shares climbed 130.1% in the mid-day session.
Benzinga · 04/04 17:21
BRNS, UPC and KWE among mid-day movers
On the Move BRNS, UPC and KWE among mid-day movers. Allurion Technologies (ALUR) and Candel Therapeutics (CADL) Gainers: Allurion and HWH. Losers: eFFECTOR and AXT.
Seeking Alpha · 04/04 17:06
12 Health Care Stocks Moving In Thursday's Intraday Session
Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. Macrogenics ( NASDAQ:MGNX) stock rose 32.55% during the session. Barinthus Biotherapeutics shares increased by 29.55%.
Benzinga · 04/04 16:31
The Latest Analyst Ratings For Macrogenics
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The average price target for Macrogenics is $21.8, with a 12-month price target of $29.00. The company has a strong pipeline of product candidates. 10 analysts have expressed a variety of opinions on the company over the past quarter.
Benzinga · 04/04 16:01
BUZZ-U.S. STOCKS ON THE MOVE-Delta Air Lines, Alternus Clean Energy, US banks
Wall Street's main stock indexes advanced on Thursday. Dow Jones Industrial Average was up 0.41% at 39,288.94. Delta Air Lines and Alternus Clean Energy were among the biggest decliners on the New York Stock Exchange. The Nasdaq composite and S&P 500 were both up.
Reuters · 04/04 15:52
Hawkish Fed Comments Knock Stocks Lower
S&P 500 and Nasdaq 100 drop to 2-week lows; Dow Jones Industrials fall to a 2-1/2 week low. Stocks initially opened higher after hawkish Fed comments. European stock markets closed higher. T-note yields turn lower after US weekly jobless claims report rose more than expected to two-month high. Hawkish Fed comments limited gains in T-notes.
Barchart · 04/04 15:49
More
Webull provides a variety of real-time MGNX stock news. You can receive the latest news about Macrogenics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.